Larimar Therapeutics, Inc.

NasdaqGM:LRMR Stok Raporu

Piyasa değeri: US$493.9m

Larimar Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Larimar Therapeutics CEO'su Carole Ben-Maimon, May2020 tarihinde atandı, in görev süresi 4.5 yıldır. in toplam yıllık tazminatı $ 3.14M olup, şirket hissesi ve opsiyonları dahil olmak üzere 17.8% maaş ve 82.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.18% ine doğrudan sahiptir ve bu hisseler $ 875.22K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 4.3 yıldır.

Anahtar bilgiler

Carole Ben-Maimon

İcra Kurulu Başkanı

US$3.1m

Toplam tazminat

CEO maaş yüzdesi17.8%
CEO görev süresi4.5yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi4.3yrs
Yönetim Kurulu ortalama görev süresi4.3yrs

Son yönetim güncellemeleri

Recent updates

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Oct 07

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Aug 09
Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Larimar Therapeutics: More Data Still Needed

Jul 15

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 31

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21
We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Dec 15

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Dec 08

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

Nov 16

Larimar Therapeutics reports Q3 results

Nov 10

CEO Tazminat Analizi

Carole Ben-Maimon'un ücretlendirmesi Larimar Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$65m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$3mUS$560k

-US$37m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$2mUS$528k

-US$35m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$2mUS$510k

-US$51m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$49m

Mar 31 2021n/an/a

-US$48m

Dec 31 2020US$5mUS$268k

-US$42m

Tazminat ve Piyasa: Carole 'ın toplam tazminatı ($USD 3.14M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.40M ).

Tazminat ve Kazançlar: Carole şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Carole Ben-Maimon (65 yo)

4.5yrs

Görev süresi

US$3,137,432

Tazminat

Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Carole Ben-Maimon
CEO, President & Director4.5yrsUS$3.14m0.18%
$ 875.2k
Michael Celano
Secretary & CFO4.5yrsUS$1.42m0.087%
$ 431.5k
Gopi Shankar
Chief Development Officer1.8yrsUS$1.43m0.0078%
$ 38.7k
John Berman
Vice President of Finance & Administration1.3yrsVeri yokVeri yok
Jennifer Johansson
Vice President of Legal & Compliance7.9yrsVeri yokVeri yok
Russell Clayton
Chief Medical Officer1.3yrsVeri yokVeri yok
Francis Conway
VP & Controller4.3yrsVeri yokVeri yok

4.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim: LRMR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Carole Ben-Maimon
CEO, President & Director4.5yrsUS$3.14m0.18%
$ 875.2k
Jonathan Leff
Independent Director4.5yrsUS$79.96kVeri yok
Jeffrey Sherman
Independent Director1.1yrsUS$56.43k0%
$ 0
Frank Thomas
Independent Director10.4yrsUS$86.21k0.0031%
$ 15.5k
Thomas Hamilton
Independent Director4.5yrsUS$77.77k0.89%
$ 4.4m
Joseph Truitt
Independent Chairman of the Board4.5yrsUS$114.96k0.0043%
$ 21.3k
Giovanni Manfredi
Member of Scientific Advisory Board4.1yrsVeri yokVeri yok
Mark Payne
Member of Scientific Advisory Board4.1yrsVeri yokVeri yok
Marni Falk
Member of Scientific Advisory Board4.1yrsVeri yokVeri yok
Jill Ostrem
Member of Scientific Advisory Board2.2yrsVeri yokVeri yok

4.3yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LRMR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).